High levels of 150-kDa insulin-like growth factor binding protein three ternary complex in patients with acromegaly and the effect of pegvisomant-induced serum IGF-1 normalization

Growth Hormone and IGF Research

Volumn 14, Issue 1, 2004, Pages 59-65

  Parkinson, Craig ^a   Flyvbjerg, Allan ^b   Trainer, Peter J ^c  

^a IPSWICH HOSPITAL   (United Kingdom)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Acromegaly; Insulin like growth factor binding protein 3; Insulin like growth factor I; Pegvisomant; Ternary complex

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; ESTROGEN; GLUCOCORTICOID; GROWTH HORMONE; GROWTH HORMONE RECEPTOR; OCTREOTIDE; PEGVISOMANT; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TESTOSTERONE; THYROXINE;

ACROMEGALY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPLEX FORMATION; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; IN VIVO STUDY; MALE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; RADIOIMMUNOASSAY; RECEPTOR BLOCKING; REFERENCE VALUE; STUDENT T TEST; WESTERN BLOTTING;

EID: 0347135729     PISSN: 10966374     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ghir.2003.08.004     Document Type: Article

References (53)

1. S. Melmed, Acromegaly, N. Engl. J. Med. 322 (1990) 966-977.
2. D.R. Clemmons, J.J. Van Wyk, E.C. Ridgway, B. Kliman, R.N. Kjellberg, L.E. Underwood, Evaluation of acromegaly by radio-immunoassay of somatomedin-C, N. Engl. J. Med. 301 (1979) 1138-1142.
3. A. Giustina, A. Barkan, F.F. Casanueva, F. Cavagnini, L. Frohman, K. Ho, J. Veldhuis, J. Wass, K. Von Werder, S. Melmed, Criteria for cure of acromegaly: a consensus statement, J. Clin. Endocrinol. Metab. 85 (2000) 526-529.
4. A.L. Barkan, I.Z. Beitins, R.P. Kelch, Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion, J. Clin. Endocrinol. Metab. 67 (1988) 69-73.
5. S. Shimasaki, M. Shimonaka, H.P. Zhang, N. Ling, Identification of five different insulin-like growth factor binding proteins (IGFBPs) from adult rat serum and molecular cloning of a novel IGFBP-5 in rat and human, J. Biol. Chem. 266 (1991) 10646-10653.
6. S. Shimasaki, L. Gao, M. Shimonaka, N. Ling, Isolation and molecular cloning of insulin-like growth factor-binding protein-6, Mol. Endocrinol. 5 (1991) 938-948.
7. J.I. Jones, D.R. Clemmons, Insulin-like growth factors and their binding proteins: biological actions, Endocr. Rev. 16 (1995) 3-34.
8. W.H. Daughaday, M. Kapadia, I.K. Mariz, Serum somatomedin binding proteins: physiologic significance and interference in radioligand assay, J. Lab. Clin. Med. 109 (1986) 335-363.
9. S. Mohan, D.J. Baylink, Development of a simple valid method for the complete removal of insulin-like growth factor (IGF)-binding proteins from IGFs in human serum and other biological fluids: comparison with acid-ethanol treatment and C18 Sep-Pak separation, J. Clin. Endocrinol. Metab. 80 (1995) 637-647.
10. R.G. Rosenfeld, S.E. Gargosky, Assays for insulin-like growth factors and their binding proteins: practicalities and pitfalls, J. Pediatr. 125 (1996) S52-57.
11. M.B. Ranke, U. Feldt-Rasmussen, P. Bang, R.C. Baxter, C. Camacho-Hubner, D.R. Clemmons, A. Juul, H. Orskov, C.J. Strasburger, How should insulin-like growth factor I be measured. A consensus statement, Horm. Res. 55 (Suppl. 2) (2001) 106-109.
12. S. Grinspoon, D.R. Clemmons, B. Swearingen, et al., Serum insulin-like binding protein-3 levels in the diagnosis of acromegaly, J. Clin. Endocrinol. Metab. 80 (1995) 927-932.
13. M. Arosio, S. Garrone, P. Bruzzi, G. Faglia, F. Minuto, A. Barreca, Diagnostic value of the acid-labile subunit in acromegaly: evaluation in comparison with insulin-like growth factor (IGF) I, and IGF-binding protein-1, -2, and -3, J. Clin. Endocrinol. Metab. 86 (2001) 1091-1098.
14. I. Halperin, R. Casamitjana, L. Flores, et al., The role of IGF binding protein-3 as a parameter of disease activity in acromegalic patients, Eur. J. Endocrinol. 141 (1999) 145-148.
15. P. Marzullo, C. Di Somma, K.L. Pratt, J. Khosravi, A. Diamandis, G. Lombardi, A. Colao, R.G. Rosenfeld, Usefulness of different biochemical markers of the insulin-like growth factor (IGF) family in diagnosing growth hormone excess and deficiency in adults, J. Clin. Endocrinol. Metab. 86 (2001) 3001-3008.
16. H.S. Chen, H.D. Lin, Serum IGF-I and IGFBP-3 levels for the assessment of disease activity of acromegaly, J. Endocrinol. Invest. 22 (1999) 98-103.
17. B. Stoffel-Wagner, W. Springer, F. Bidlingmaier, D. Klingmuller, A comparison of different methods for diagnosing acromegaly, Clin. Endocrinol. (Oxf.) 46 (1997) 531-537.
18. S. Rajaram, D.J. Baylink, S. Mohan, Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions, Endocr. Rev. 18 (1997) 801-831.
19. C. Lassarre, M. Binoux, Insulin-like growth factor binding protein-3 is functionally altered in pregnancy plasma, Endocrinology 134 (1994) 1254-1262.
20. C. Blat, J. Villaudy, M. Binoux, In vivo proteolysis of serum insulin-like growth factor (IGF) binding protein-3 results in increased availability of IGF to target cells, J. Clin. Invest. 93 (1994) 2286-2290.
21. P. Hossenlopp, B. Segovia, C. Lassarre, M. Roghani, M. Bredon, M. Binoux, Evidence of enzymatic degradation of insulin-like growth factor-binding proteins in the 150K complex during pregnancy, J. Clin. Endocrinol. Metab. 71 (1990) 797-805.
22. L.C. Giudice, E.M. Farrell, H. Pham, G. Lamson, R.G. Rosenfeld, Insulin-like growth factor binding proteins in maternal serum throughout gestation and in the puerperium: effects of a pregnancy-associated serum protease activity, J. Clin. Endocrinol. Metab. 71 (1990) 806-816.
23. A.M. Cotterill, J.M. Holly, A.M. Taylor, S.C. Davies, V.J. Coulson, M.A. Preece, J.A. Wass, M.O. Savage, The insulin-like growth factor (IGF)-binding proteins and IGF bioactivity in Laron-type dwarfism, J. Clin. Endocrinol. Metab. 74 (1992) 56-63.
24. A.C. Timmins, A.M. Cotterill, S.C. Hughes, J.M. Holly, R.J. Ross, W. Blum, C.J. Hinds, Critical illness is associated with low circulating concentrations of insulin-like growth factors-I and -II, alterations in insulin-like growth factor binding proteins, and induction of an insulin-like growth factor binding protein 3 protease, Crit. Care Med. 24 (1996) 1460-1466.
25. A. Bereket, C.H. Lang, S.L. Blethen, J. Fan, R.A. Frost, T.A. Wilson, Insulin-like growth factor binding protein-3 proteolysis in children with insulin-dependent diabetes mellitus: a possible role for insulin in the regulation of IGFBP-3 protease activity, J. Clin. Endocrinol. Metab. 80 (1995) 2282-2288.
26. P. Bang, K. Brismar, R.G. Rosenfeld, Increased proteolysis of insulin-like growth factor-binding protein-3 (IGFBP-3) in noninsulin-dependent diabetes mellitus serum, with elevation of a 29-kilodalton (kDa) glycosylated IGFBP-3 fragment contained in the approximately 130- to 150-kDa ternary complex, J. Clin. Endocrinol. Metab. 78 (1994) 1119-1127.
27. S.C. Cwyfan-Hughes, A.M. Cotterill, A.R. Molloy, T.B. Cassell, N. Braude, C.J. Hinds, J.A. Wass, J.M. Holly, The induction of specific proteases for insulin-like growth factor-binding proteins following major heart surgery, J. Endocrinol. 135 (1992) 135-145.
28. C. Lalou, M. Binoux, Evidence that limited proteolysis of insulin-like growth factor binding protein-3 (IGFBP-3) occurs in the normal state outside of the bloodstream, Regul. Pept. 48 (1993) 179-188.
29. P. Epaminonda, S. Porretti, V. Cappiello, P. Beck-Peccoz, G. Faglia, M. Arosio, Efficacy of radiotherapy in normalizing serum IGF-I, acid-labile subunit (ALS) and IGFBP-3 levels in acromegaly, Clin. Endocrinol. 55 (2001) 183-189.
30. A.J. van der Lely, R.K. Hutson, P.J. Trainer, G.M. Besser, L. Katznelson, A. Klibanski, V. Herman-Bonert, S. Melmed, M.L. Vance, P.U. Freda, P.M. Stewart, K.E. Friend, D.R. Clemmons, G. Johannsson, S. Stavrou, D.M. Cook, L.S. Phillips, C.J. Strasburger, S. Hackett, K.A. Zib, R.J. Davis, J.A. Scarlett, M.O. Thorner, Long-term treatment of acromegaly with pegvisomant, a growth hormone antagonist, Lancet 358 (2001) 1754-1759.
31. P.J. Trainer, W.M. Drake, L. Katznelson, P.U. Freda, V. Herman-Bonert, A.J. van der Lely, E.V. Dimaraki, P.M. Stewart, K.E. Friend, M.L. Vance, G.M. Besser, J.A. Scarlett, M.O. Thorner, C. Parkinson, A. Klibanski, J.S. Powell, A.L. Barkan, M.C. Sheppard, M. Malsonado, D.R. Rose, D.R. Clemmons, G. Johannsson, B.A. Bengtsson, S. Stavrou, D.L. Kleinberg, D.M. Cook, L.S. Phillips, M. Bidlingmaier, C.J. Strasburger, S. Hackett, K. Zib, W.F. Bennett, R.J. Davis, Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant, N. Engl. J. Med. 342 (2000) 1171-1177.
32. S.E. Gargosky, P. Tapanainen, R.G. Rosenfeld, Administration of growth hormone (GH), but not insulin-like growth factor-I (IGF-I), by continuous infusion can induce the formation of the 150-kilodalton IGF-binding protein-3 complex in GH-deficient rats, J. Clin. Endocrinol. Metab. 134 (1994) 2267-2276.
33. A. Flyvbjerg, U. Kessler, B. Dorka, B. Funk, H. Orskov, W. Kiess, Transient increase in renal insulin-like growth factor binding proteins during initial kidney hypertrophy in experimental diabetes in rats, Diabetologia 35 (1992) 589-593.
34. P. Hossenlopp, D. Seurin, B. Segovia-Quinson, S. Hardouin, M. Binoux, Analysis of serum insulin-like growth factor binding proteins using western blotting: use of the method for titration of the binding proteins and competitive binding studies, Anal. Biochem. 154 (1986) 138-143.
35. S.W. Lamberts, P. Uitterlinden, T. Verleun, Relationship between growth hormone and somatomedin-C levels in untreated acromegaly, after surgery and radiotherapy and during medical therapy with sandostatin (SMS 201-995), Eur. J. Clin. Invest. (1987) 354-359.
36. B. Swearingen, F.G. Barker, L. Katznelson, B.M. Biller, S. Grinspoon, A. Klibanski, N. Moayeri, P.M. Black, N.T. Zervas, Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly, J. Clin. Endocrinol. Metab. 83 (1998) 3419-3426.
37. J.J. Kopchick, C. Parkinson, E.C. Stevenc, P.J. Trainer, Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly, Endocr. Rev. 23 (2002) 623-646.
38. S.R. Peacey, A.A. Toogood, J.D. Veldhuis, M.O. Thorner, S.M. Shalet, The relationship between 24-h growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy, J. Clin. Endocrinol. Metab. 86 (2001) 259-266.
39. C. Parkinson, W.D.J. Ryder, P.J. Trainer, The relationship between serum GH and serum IGF-I in acromegaly is gender-specific, J. Clin. Endocrinol. Metab. 86 (1001) 5240-5244.
40. C. Parkinson, A.G. Renehan, W.D. Ryder, S.T. O'Dwyer, S.M. Shalet, P.J. Trainer, Gender and age influence the relationship between serum GH and IGF-I in patients with acromegaly, Clin. Endocrinol. (Oxf.) 57 (2002) 59-64.
41. W.W. de Herder, A.J. van der Lely, J.A.M.J. Janssen, P. Uitterlinden, L.J. Holland, S.W.J. Lamberts, IGFBP-3 is a poor parameter for assessment of clinical ativity in acromegaly, Clin. Endocrinol. 43 (1995) 501-505.
42. J.P. Thissen, J.M. Ketelslegers, D. Maiter, Use of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 in the diagnosis of acromegaly and growth hormone deficiency in adults, Growth Regul. 6 (1996) 222-229.
43. C. Paramo, O.M.A. Andrade, E. Fluiters, R. Luna, J. de la Fuente, R.V. Garcia-Mayor, Comparative study of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) level and IGF-I/IGFBP-3 ratio measurements and their relationship with an index of clinical activity in the management of patients with acromegaly, Metabolism 46 (1997) 494-498.
44. T. Laursen, A. Flyvbjerg, J.O. Jorgensen, R.C. Baxter, J.S. Christiansen, Stimulation of the 150-kilodalton insulin-like growth factor-binding protein-3 ternary complex by continuous and pulsatile patterns of growth hormone (GH) administration in GH-deficient patients, J. Clin. Endocrinol. Metab. 85 (2000) 4310-4314.
45. C. Skjaerbaek, A. Kaal, J. Moller, N. Vahl, J. Weeke, H. Orskov, A. Flyvbjerg, No effect of growth hormone on serum insulin-like growth factor binding protein-3 proteolysis, J. Clin. Endocrinol. Metab. 83 (1998) 1206-1210.
46. C. Lassarre, C. Lalou, L. Perin, M. Binoux, Protease-induced alteration of insulin-like growth factor binding protein-3 as detected by radioimmunoassay. Agreement with ligand blotting data, Growth Regul. 4 (1994) 48-55.
47. C. Lassarre, F. Duron, M. Binoux, Use of the ligand immunofunctional assay for human insulin-like growth factor (IGF) binding protein-3 (IGFBP-3) to analyze IGFBP-3 proteolysis and igf-i bioavailability in healthy adults, GH-deficient and acromegalic patients, and diabetics, J. Clin. Endocrinol. Metab. 86 (2001) 1942-1952.
48. P.D. Lee, L.C. Giudice, C.A. Conover, D.R. Powell, Insulin-like growth factor binding protein-1: recent findings and new directions, Proc. Soc. Exp. Biol. Med. 216 (1997) 319-357.
49. J. Zapf, Physiological role of the insulin-like growth factor binding proteins, Eur. J. Endocrinol. 132 (1995) 645-654.
50. A. Juul, K. Main, W.F. Blum, J. Lindholm, M.B. Ranke, N.E. Skakkebaek, The ratio between serum levels of insulin-like growth factor (IGF)-I and the IGF binding proteins (IGFBP-1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients, Clin. Endocrinol. (Oxf.) 41 (1994) 85-93.
51. J.M. Holly, A.M. Cotterill, R.C. Jemmott, D. Shears, S. al-Othman, T. Chard, J.A. Wass, Inter-relations between growth hormone, insulin, insulin-like growth factor-I (IGF-I), IGF-binding protein-1 (IGFBP-1) and sex hormone-binding globulin in acromegaly, Clin. Endocrinol. (Oxf.) 34 (1991) 275-280.
52. J.O. Jorgensen, N. Moller, J. Moller, J. Weeke, W.F. Blum, Insulin-like growth factors (IGF)-I and -II and IGF binding protein-1, -2, and -3 in patients with acromegaly before and after adenomectomy, Metabolism 43 (1994) 579-583.
53. A.G. Renehan, A.A. Toogood, W.D. Ryder, J. Zones, C.S. Potten, S.T. O'Dwyer, S.M. Shalet, Paradoxical elevations in serum IGF-II and IGF binding protein-2 in acromegaly: insights into the regulation of these peptides, Clin. Endocrinol. 55 (2001) 469-475.